Neuland Laboratories Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/prz0yn1nwv4xca6zymf0ku9u.pdf

Key Takeaways


Quarterly Performance & Lumpiness

Davuluri: "As individual commercial shipments become larger, a shift in timing can have a greater impact on quarterly revenues, and that is why we keep saying lumpiness, quite often in our earnings calls and conversations. This makes growth uneven from a quarter-to-quarter basis, and that is why we keep saying that we need to assess our business over longer periods."

Peptide Build-Out

Davuluri: "The Module 2, Module 3, Module 4, which is the peptide investment, will get triggered if Module 1 gets occupied and if we have some kind of negative impact in our current CMS business or commercial business, we would still continue with those investments because we believe that there is a sustained demand for peptide API."

Pipeline & Customer Evolution

Davuluri: "I think we are fairly certain that there will be no impact because of the dip from these molecules on the growth that is going to come, which... will not just be from peptides, there will also be complex small molecules, there will be other products as well."

Infrastructure & Capacity Expansion

Davuluri: "I would probably urge investors to look at the investment in Kakinada more from a long-term return perspective rather than something that will give us returns in the immediate timeframe."

Peptide Industry Context & Competitive Positioning

Davuluri: "Lot of players who are just putting in reactors and expecting customers to come and do the technology transfer, I believe that they may face more challenges because the moment that customer goes away they only are sitting with equipment and not necessarily capabilities, but if you have strong R&D capabilities in peptides, then you are also able to cater to these other 1000 molecules."

Guidance & Commitments

CommitmentSpecificsTimeline
H2 FY27 growthGrowth expectations remain intact for H2 FY27 and the following financial yearH2 FY27 and FY28
Peptide PPQ revenuesPPQ-related revenues from peptides to begin6–9 months
Peptide first commercial revenuesMSA and first commercial batch shipping after PPQ completion~1.5–2 years
Specialty segment normalizationBusiness to normalize based on customer feedbackBy Q4 FY27
Peptide Module 2 configurationFinalize configuration and investment planNext 3–6 months
Process R&D centerFully operationalEarly next year
More CMS launchesAdditional launches expectedNext 1–2 years
Peptide Modules 2–4 triggerInvestment triggered if Module 1 gets occupied; will proceed even if CMS business faces headwindsConditional on Module 1 occupancy
Kakinada expansionCould reach ~200 acres depending on business growth plansOver the next two years

Key Metrics

MetricQ2 FY27
Total income₹457.2 cr, vs ₹516.1 cr in Q2 FY26
Total income (H1 FY27)₹1,107.2 cr, vs ₹816.7 cr in H1 FY26
Gross margin59.4%, vs 60.1% in Q2 FY26
EBITDA₹104.6 cr, margin 22.9% vs ₹156.9 cr and 30.4% in Q2 FY26
Profit after tax₹51.1 cr, vs ₹96.5 cr in Q2 FY26
EPS₹39.85 per share
CMS revenue₹214 cr, recognized from 5 or 6 molecules this quarter
Working capital104 days of sale, vs 84 days in Q1 FY27
Capex outflow (H1 FY27)₹261 cr
Free cash flows (H1 FY27)₹99 cr
Net debtnegative ₹208 cr
Top 5 customer concentration68% of revenues
DMFs filed during the period2, Fezolinetant and Ivacaftor
Phase 3 projects13, up from 8 (per an analyst's math)
Land acquired at Kakinada~134 acres, with first right of refusal on additional ~60 acres